Trade Zai Lab Limited - ZLAB CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.42 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 33.67 |
| Open | 32.54 |
| 1-Year Change | 108.86% |
| Day's Range | 31.54 - 32.54 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2025 | 31.82 | -0.92 | -2.81% | 32.74 | 32.74 | 31.50 |
| Apr 24, 2025 | 33.67 | 0.78 | 2.37% | 32.89 | 33.80 | 32.53 |
| Apr 23, 2025 | 33.35 | -0.01 | -0.03% | 33.36 | 34.46 | 33.32 |
| Apr 22, 2025 | 32.22 | 1.01 | 3.24% | 31.21 | 32.48 | 31.12 |
| Apr 21, 2025 | 29.63 | 1.02 | 3.57% | 28.61 | 29.83 | 28.48 |
| Apr 17, 2025 | 28.78 | 0.61 | 2.17% | 28.17 | 28.94 | 28.17 |
| Apr 16, 2025 | 28.82 | -0.18 | -0.62% | 29.00 | 29.40 | 28.16 |
| Apr 15, 2025 | 30.21 | -0.28 | -0.92% | 30.49 | 31.04 | 29.79 |
| Apr 14, 2025 | 31.22 | -0.02 | -0.06% | 31.24 | 33.17 | 30.83 |
| Apr 11, 2025 | 29.49 | 1.71 | 6.16% | 27.78 | 29.81 | 27.59 |
| Apr 10, 2025 | 24.18 | -2.52 | -9.44% | 26.70 | 28.63 | 24.01 |
| Apr 9, 2025 | 26.92 | 0.17 | 0.64% | 26.75 | 27.85 | 24.59 |
| Apr 8, 2025 | 26.98 | -2.36 | -8.04% | 29.34 | 29.55 | 26.13 |
| Apr 7, 2025 | 28.71 | 0.06 | 0.21% | 28.65 | 30.73 | 27.63 |
| Apr 4, 2025 | 31.68 | -2.74 | -7.96% | 34.42 | 34.46 | 31.07 |
| Apr 3, 2025 | 36.55 | 0.72 | 2.01% | 35.83 | 37.76 | 35.83 |
| Apr 2, 2025 | 36.31 | 0.36 | 1.00% | 35.95 | 36.37 | 35.15 |
| Apr 1, 2025 | 37.21 | -0.41 | -1.09% | 37.62 | 38.20 | 36.84 |
| Mar 31, 2025 | 36.06 | 0.86 | 2.44% | 35.20 | 36.77 | 34.37 |
| Mar 28, 2025 | 37.20 | -1.91 | -4.88% | 39.11 | 39.69 | 36.49 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Zai Lab Limited Company profile
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC. The company's drug candidates also comprise ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; and ZL-2302 to treat non-small cell lung cancer. The company, through its subsidiary, Zai Lab (Shanghai) Co. Ltd., has a collaboration agreement with the NovoCure Limited to perform clinical studies, sell, and import tumor treating field products in the field of oncology. Zai Lab Limited was founded in 2013 and is headquartered in Shanghai, the People's Republic of China.| Industry: | Biopharmaceuticals |
4560 Jinke Road
Bldg. 1, 4/F
SHANGHAI
SHANGHAI 201210
CN
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com